drugset
drugset / Trial / NCT06497699

A Real-world Study of DEXYCU in the Treatment of Inflammation After Cataract Surgery

NCT06497699 ↗

Phase 4 Completed 263 enrolled Ocumension Therapeutics (Shanghai) Co., Ltd
Non-randomizedParallel-groupOpen-labelTreatment

Summary

This is a prospective, real-world study aimed to evaluate the efficacy and safety of Dexycu in treating postoperative inflammation of cataracts.

Timeline

Start
2021-10-28
Primary completion
2023-07-08
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Dexamethasone Small molecule 517 ug Other

Indications

cataract